Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune

▴ Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune
After, Covishield's first shot, tests related to COVID-19 and antibodies came negative, officials said

Second Phase clinical trials of Oxford COVID-19 vaccine begin in Chennai and Pune. In Chennai, two prominent medical institutions are starting the second and third phase field trial of the Oxford vaccine candidate Covishield.

In another development, the Tamil Nadu Government has exempted college students having arrears except in the last semester from writing the examinations, in view of Covid-19. Previously the exemption has been made for the regular students.

Meanwhile, the total number of COVID-19 infections in the state is nearing the four lakh mark. 5958 people were tested positive yesterday taking the total to over 3,97000. However, the active caseload in the state is about 52 thousand.

Chennai is one of the seventeen locations in India to conduct the field trial of the promising vaccine candidate Covishield, developed jointly by the Oxford University and AstraZeneca. The Government Rajiv Gandhi General Hospital and the Sri Ramachandra Institute of Higher Education and Research are the two institutions in the city that run the trial.

The state director of public health Dr TS Selva Vinayagam, who coordinates the study in Chennai, told , healthy volunteers above the age of 18 are being involved in its multi-centric clinical trial. Dr TS Selva Vinayagam, Director, Public Health said, “We will be starting the Phase-2 and Phase-3 together. We will be following the volunteers for up to 180 days. This is to assess the safety, immunogenicity and reacto-genecity. We will be doing that.” The T-cells in the white blood corpuscles against the viral pathogen are said to be observed in 14-days after administering the vaccine and the antibodies in about 28 days. Their effectiveness to eliminate the virus and several other factors will be exhaustively tested during the trial.In Maharashtra, the Phase II clinical trial of the Oxford COVID-19 vaccine, being manufactured by the Serum Institute of India (SII), began at a medical college and hospital in Pune today. According to the Hospital officials, two male volunteers were administered the vaccine at Bharati Vidyapeeth's Medical College and Hospital post noon today.

Our correspondent reports, doctors at Bharati Vidyapeeth's Medical College and Hospital administered the first shot of the 'Covishield' vaccine to a 32-year-old man after his reports of COVID-19 and antibodies tests came out negative. Another 48-year-old male volunteer was also given the vaccine. According to details by the Medical Director of Bharati Vidyapeeth's Medical College Hospital and Research Centre, Dr Sanjay Lalwani, the COVID-19 and antibodies tests were conducted on the five volunteers.

Of them, the reports of three volunteers' antibodies test came out positive so they became ineligible for today's trial. The doctor informed that in all, 25 candidates will be given the vaccine in next seven days. Meanwhile, the Sangli district administration has initiated stringent action on the private hospitals which are asking to deposit advanced amount before admitting Covid positive patients. The Sangli district collector, Dr. Abhijit Choudhari said that the private hospitals cannot ask a patient to deposit advanced amount before his admission to the hospital.

Tags : #Covishield #OxfordVaccine #SerumInstitute #Pune #Chennai #Phase2trialCovidvaccine #OxfordVaccinePhase2Trial #CovishieldPhase2Trial #Astrazeneca #LatestCovidNewsAug27

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Successful Removal of 3.7 KG Large Abdominal Tumor from 14-Year-Old Somalian Girl at KIMS Cuddles HospitalMay 16, 2024
iLEAD Sets a Precedent by Launching a Graphic Anthology Authored by Multimedia, Animation and Graphics Students May 16, 2024
Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT); Achieves significant advancement in Cancer Treatment to Enhance Quality of LifeMay 16, 2024
IIITH Announces Product Management Summer SchoolMay 16, 2024
Çelebi India's Delhi Cargo Terminal Successfully Handles Airbus H125 Helicopter ShipmentMay 16, 2024
Plant-Based Diets and Prostate Cancer: New UCSF Study Shows Promising ResultsMay 16, 2024
National Medical Commission Approves 112 New Medical CollegesMay 16, 2024
Study Suggests That Chemotherapy Results in Physical Decline for Older Women with Breast CancerMay 16, 2024
Google DeepMind's AlphaFold 3: Revolutionizing Drug Discovery with AIMay 16, 2024
Hester Biosciences Ltd reports Consolidated Revenue growth of 18% at Rs. 79.3 crore, EBITDA up 37% to Rs. 16.4 crore and Net Profit up 12% to Rs. 6.40 crore in Q4FY24May 16, 2024
Akshay Tritiya Parna Mahotsav heldMay 16, 2024
IT Minister Sridhar Babu to grace the 10th National Facilities Managers Summit-2024, to be held in the cityMay 15, 2024
Alarming Study Reveals Cancer-Causing Chemicals in Car InteriorsMay 15, 2024
India's Thalassemia Challenge: The Importance of Early Screening and TreatmentMay 15, 2024
The Dangers of Ultra-Processed Foods: A 30-Year Study Raises AlarmsMay 15, 2024
Unique Genetic Risk Factors for Breast Cancer Found in African Ancestry StudyMay 15, 2024
AsiaMedic partners with Sunway to establish new diagnostic imaging centreMay 14, 2024
Kamineni Doctors Successfully Remove Bone Stuck Near Heart in Elderly PatientMay 14, 2024
On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology NursesMay 14, 2024
Shiprocket announces Shiprocket Growth Academy to upskill 100,000 Indian MSMEs through eCommerce learningMay 14, 2024